Diagnostic biomarkers of differentiated thyroid cancer

Endocrine

Volumn 44, Issue 3, 2013, Pages 616-622

  Kunavisarut, Tada ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Diagnostic biomarkers; Differentiated thyroid cancer; Fine needle aspiration (FNA); Thyroid nodule

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CYTOKERATIN 19; GALECTIN 3; HECTOR BATTIFORA MESOTHELIAL ANTIGEN 1; MICRORNA; MONOCLONAL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

BRAF GENE; CANCER DIAGNOSIS; COST EFFECTIVENESS ANALYSIS; DIFFERENTIATED THYROID CANCER; DISEASE ASSOCIATION; DISEASE MARKER; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENOME ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DYNAMICS; ONCOGENE; ONCOGENE RAS; OUTCOME ASSESSMENT; PAIRED BOX GENE 8 GENE; PATIENT ASSESSMENT; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEOMICS; PTC GENE; RET GENE; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOPSY, FINE-NEEDLE; HUMANS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 84890786203     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9974-2     Document Type: Review

References (76)

1. L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295(18), 2164-2167 (2006)
2. S. Liu, R. Semenciw, A.M. Ugnat, Y. Mao, Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br. J. Cancer 85(9), 1335-1339 (2001)
3. J.R. Burgess, Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982-1997). Thyroid 12(2), 141-149 (2002)
4. M. Colonna, P. Grosclaude, L. Remontet, C. Schvartz, J. Mace-Lesech, M. Velten, A. Guizard, B. Tretarre, A.V. Buemi, P. Arveux, J. Esteve, Incidence of thyroid cancer in adults recorded by French cancer registries (1978-1997). Eur. J. Cancer 38(13), 1762-1768 (2002)
5. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167-1214 (2009)
6. H. Gharib, J.R. Goellner, Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann. Intern. Med. 118(4), 282-289 (1993)
7. H. Gharib, E. Papini, R. Paschke, D.S. Duick, R. Valcavi, L. Hegedus, P. Vitti, American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr. Pract. 16(Suppl 1), 1-43 (2010)
8. E.S. Cibas, S.Z. Ali, The Bethesda System for reporting thyroid cytopathology. Thyroid 19(11), 1159-1165 (2009)
9. V.Y. Jo, E.B. Stelow, S.M. Dustin, K.Z. Hanley, Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am. J. Clin. Pathol. 134(3), 450-456 (2010)
10. E.B. Stelow, C. Woon, K.A. Atkins, R.H. Bardales, H.P. Cathro, H.F. Frierson Jr, M.W. Stanley, K. Savik, S.E. Pambuccian, Interobserver variability with the interpretation of thyroid FNA specimens showing predominantly Hurthle cells. Am. J. Clin. Pathol. 126(4), 580-583 (2006)
11. K.M. Clary, J.L. Condel, Y. Liu, D.R. Johnson, D.M. Grzybicki, S.S. Raab, Interobserver variability in the fine needle aspiration biopsy diagnosis of follicular lesions of the thyroid gland. Acta Cytol. 49(4), 378-382 (2005)
12. R. Gerhard, G. da Cunha Santos, Inter- and intraobserver reproducibility of thyroid fine needle aspiration cytology: an analysis of discrepant cases. Cytopathology 18(2), 105-111 (2007)
13. Nasrollah, N., Trimboli, P., Guidobaldi, L., Cicciarella Modica, D.D., Ventura, C., Ramacciato, G., Taccogna, S., Romanelli, F., Valabrega, S., Crescenzi, A.: Thin core biopsy should help to discriminate thyroid nodules cytologically classified as indeterminate. A new sampling technique. Endocrine (2012)
14. N. Dhomen, R. Marais, New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev. 17(1), 31-39 (2007)
15. I. Palona, H. Namba, N. Mitsutake, D. Starenki, A. Podtcheko, I. Sedliarou, A. Ohtsuru, V. Saenko, Y. Nagayama, K. Umezawa, S. Yamashita, BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147(12), 5699-5707 (2006)
16. M.C. Zatelli, G. Trasforini, S. Leoni, G. Frigato, M. Buratto, F. Tagliati, R. Rossi, L. Cavazzini, E. Roti, E.C. degli Uberti, BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur. J. Endocrinol. 161(3), 467-473 (2009)
17. M. Xing, BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12(2), 245-262 (2005)
18. Y.E. Nikiforov, D.L. Steward, T.M. Robinson-Smith, B.R. Haugen, J.P. Klopper, Z. Zhu, J.A. Fagin, M. Falciglia, K. Weber, M.N. Nikiforova, Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab. 94(6), 2092-2098 (2009)
19. S.W. Kim, J.I. Lee, J.W. Kim, C.S. Ki, Y.L. Oh, Y.L. Choi, J.H. Shin, H.K. Kim, H.W. Jang, J.H. Chung, BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J. Clin. Endocrinol. Metab. 95(8), 3693-3700 (2010)
20. E. Brzezianska, D. Pastuszak-Lewandoska, K. Wojciechowska, M. Migdalska-Sek, A. Cyniak-Magierska, E. Nawrot, A. Lewinski, Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol. Lett. 28(4), 351-359 (2007)
21. G. Oler, J.M. Cerutti, High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 115(5), 972-980 (2009)
22. K.H. Kim, D.W. Kang, S.H. Kim, I.O. Seong, D.Y. Kang, Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med. J. 45(5), 818-821 (2004)
23. S. Girlando, L.V. Cuorvo, M. Bonzanini, L. Morelli, P. Amadori, P. Dalla Palma, M. Barbareschi, High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy. Int. J. Surg. Pathol. 18(3), 173-176 (2010)
24. Y.E. Nikiforov, Molecular diagnostics of thyroid tumors. Arch. Pathol. Lab. Med. 135(5), 569-577 (2011)
25. V. Vasko, M. Ferrand, J. Di Cristofaro, P. Carayon, J.F. Henry, C. de Micco, Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 88(6), 2745-2752 (2003)
26. V.V. Vasko, J. Gaudart, C. Allasia, V. Savchenko, J. Di Cristofaro, M. Saji, M.D. Ringel, C. De Micco, Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur. J. Endocrinol. 151(6), 779-786 (2004)
27. P.E. Macchia, P. Lapi, H. Krude, M.T. Pirro, C. Missero, L. Chiovato, A. Souabni, M. Baserga, V. Tassi, A. Pinchera, G. Fenzi, A. Gruters, M. Busslinger, R. Di Lauro, PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat. Genet. 19(1), 83-86 (1998)
28. M. Pasca di Magliano, R. Di Lauro, M. Zannini, Pax8 has a key role in thyroid cell differentiation. Proc. Natl. Acad. Sci. U S A 97(24), 13144-13149 (2000)
29. N.L. Eberhardt, S.K. Grebe, B. McIver, H.V. Reddi, The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol. Cell. Endocrinol. 321(1), 50-56 (2010)
30. T. Dwight, S.R. Thoppe, T. Foukakis, W.O. Lui, G. Wallin, A. Hoog, T. Frisk, C. Larsson, J. Zedenius, Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 88(9), 4440-4445 (2003)
31. A.R. Marques, C. Espadinha, A.L. Catarino, S. Moniz, T. Pereira, L.G. Sobrinho, V. Leite, Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 87(8), 3947-3952 (2002)
32. M.N. Nikiforova, R.A. Lynch, P.W. Biddinger, E.K. Alexander, G.W. Dorn 2nd, G. Tallini, T.G. Kroll, Y.E. Nikiforov, RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88(5), 2318-2326 (2003)
33. Y. Hibi, T. Nagaya, F. Kambe, T. Imai, H. Funahashi, A. Nakao, H. Seo, Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR gamma fusion mRNA? Endocr. J. 51(3), 361-366 (2004)
34. N. Mitsutake, M. Miyagishi, S. Mitsutake, N. Akeno, C. Mesa Jr, J.A. Knauf, L. Zhang, K. Taira, J.A. Fagin, BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147(2), 1014-1019 (2006)
35. M. Xing, Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20(7), 697-706 (2010)
36. Y.E. Nikiforov, J.M. Rowland, K.E. Bove, H. Monforte-Munoz, J.A. Fagin, Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57(9), 1690-1694 (1997)
37. M. Santoro, F. Carlomagno, I.D. Hay, M.A. Herrmann, M. Grieco, R. Melillo, M.A. Pierotti, I. Bongarzone, G. Della Porta, N. Berger et al., Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest. 89(5), 1517-1522 (1992)
38. R. Elisei, C. Romei, T. Vorontsova, B. Cosci, V. Veremeychik, E. Kuchinskaya, F. Basolo, E.P. Demidchik, P. Miccoli, A. Pinchera, F. Pacini, RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab. 86(7), 3211-3216 (2001)
39. Y.E. Nikiforov, RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 13(1), 3-16 (2002)
40. N.P. Ohori, M.N. Nikiforova, K.E. Schoedel, S.O. LeBeau, S.P. Hodak, R.R. Seethala, S.E. Carty, J.B. Ogilvie, L. Yip, Y.E. Nikiforov, Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol. 118(1), 17-23 (2010)
41. B. Zhang, X. Pan, G.P. Cobb, T.A. Anderson, microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302(1), 1-12 (2007)
42. H. He, K. Jazdzewski, W. Li, S. Liyanarachchi, R. Nagy, S. Volinia, G.A. Calin, C.G. Liu, K. Franssila, S. Suster, R.T. Kloos, C.M. Croce, A. de la Chapelle, The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. U S A 102(52), 19075-19080 (2005)
43. M.N. Nikiforova, G.C. Tseng, D. Steward, D. Diorio, Y.E. Nikiforov, MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 93(5), 1600-1608 (2008)
44. F. Weber, R.E. Teresi, C.E. Broelsch, A. Frilling, C. Eng, A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab. 91(9), 3584-3591 (2006)
45. Y.T. Chen, N. Kitabayashi, X.K. Zhou, T.J. Fahey 3rd, T. Scognamiglio, MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod. Pathol. 21(9), 1139-1146 (2008)
46. Vriens, M.R., Weng, J., Suh, I., Huynh, N., Guerrero, M.A., Shen, W.T., Duh, Q.Y., Clark, O.H., Kebebew, E.: MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer (2011)
47. Keutgen, X.M., Filicori, F., Crowley, M.J., Wang, Y., Scognamiglio, T., Hoda, R., Buitrago, D., Cooper, D., Zeiger, M.A., Zarnegar, R., Elemento, O., Fahey, T.J., 3rd: A Panel of four MicroRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin. Cancer. Res. (2012)
48. D. Chudova, J.I. Wilde, E.T. Wang, H. Wang, N. Rabbee, C.M. Egidio, J. Reynolds, E. Tom, M. Pagan, C.T. Rigl, L. Friedman, C.C. Wang, R.B. Lanman, M. Zeiger, E. Kebebew, J. Rosai, G. Fellegara, V.A. LiVolsi, G.C. Kennedy, Molecular classification of thyroid nodules using high-dimensionality genomic data. J. Clin. Endocrinol. Metab. 95(12), 5296-5304 (2010)
49. D.S. Duick, J.P. Klopper, J.C. Diggans, L. Friedman, G.C. Kennedy, R.B. Lanman, B. McIver, The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid 22(10), 996-1001 (2012)
50. K. Krause, B. Jessnitzer, D. Fuhrer, Proteomics in thyroid tumor research. J. Clin. Endocrinol. Metab. 94(8), 2717-2724 (2009)
51. M.R. Castro, H. Gharib, Continuing controversies in the management of thyroid nodules. Ann. Intern. Med. 142(11), 926-931 (2005)
52. H.A. Saleh, J. Feng, F. Tabassum, O. Al-Zohaili, M. Husain, T. Giorgadze, Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal 6, 18 (2009)
53. E. Saggiorato, R. De Pompa, M. Volante, S. Cappia, F. Arecco, A.P. Dei Tos, F. Orlandi, M. Papotti, Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr. Relat. Cancer 12(2), 305-317 (2005)
54. F.T. Liu, G.A. Rabinovich, Galectins as modulators of tumour progression. Nat. Rev. Cancer 5(1), 29-41 (2005)
55. Y. Takenaka, H. Inohara, T. Yoshii, K. Oshima, S. Nakahara, S. Akahani, Y. Honjo, Y. Yamamoto, A. Raz, T. Kubo, Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett. 195(1), 111-119 (2003)
56. G. Elad-Sfadia, R. Haklai, E. Balan, Y. Kloog, Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J. Biol. Chem. 279(33), 34922-34930 (2004)
57. P. Mehrotra, A. Okpokam, R. Bouhaidar, S.J. Johnson, J.A. Wilson, B.R. Davies, T.W. Lennard, Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45(5), 493-500 (2004)
58. M. Niedziela, J. Maceluch, E. Korman, Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. J. Clin. Endocrinol. Metab. 87(9), 4411-4415 (2002)
59. A. Bartolazzi, A. Gasbarri, M. Papotti, G. Bussolati, T. Lucante, A. Khan, H. Inohara, F. Marandino, F. Orlandi, F. Nardi, A. Vecchione, R. Tecce, O. Larsson, Thyroid Cancer Study Group, Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357(9269), 1644-1650 (2001)
60. A. Sanabria, A.L. Carvalho, V. Piana de Andrade, J. Pablo Rodrigo, J.G. Vartanian, A. Rinaldo, M.K. Ikeda, K.O. Devaney, J. Magrin, F. Augusto Soares, A. Ferlito, L.P. Kowalski, Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm"? A critical appraisal of the evidence. Head Neck 29(11), 1046-1054 (2007)
61. C.G. Chiu, S.S. Strugnell, O.L. Griffith, S.J. Jones, A.M. Gown, B. Walker, I.R. Nabi, S.M. Wiseman, Diagnostic utility of galectin-3 in thyroid cancer. Am. J. Pathol. 176(5), 2067-2081 (2010)
62. A. Bartolazzi, G. Bussolati, Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 48(2), 212-213 (2006)
63. Bartolazzi, A., Papotti, M., Orlandi, F.: Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules. J. Clin. Endocrinol. Metab. 88(2), 950; author reply 950-951 (2003)
64. A. Bartolazzi, F. Orlandi, E. Saggiorato, M. Volante, F. Arecco, R. Rossetto, N. Palestini, E. Ghigo, M. Papotti, G. Bussolati, M.P. Martegani, F. Pantellini, A. Carpi, M.R. Giovagnoli, S. Monti, V. Toscano, S. Sciacchitano, G.M. Pennelli, C. Mian, M.R. Pelizzo, M. Rugge, G. Troncone, L. Palombini, G. Chiappetta, G. Botti, A. Vecchione, R. Bellocco, Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 9(6), 543-549 (2008)
65. A. Bartolazzi, C. Bellotti, S. Sciacchitano, Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules. Appl. Immunohistochem. Mol. Morphol. 20(1), 2-7 (2012)
66. A. Carpi, G. Rossi, G.D. Coscio, G. Iervasi, A. Nicolini, F. Carpi, J.I. Mechanick, A. Bartolazzi, Galectin-3 detection on large-needle aspiration biopsy improves preoperative selection of thyroid nodules: a prospective cohort study. Ann. Med. 42(1), 70-78 (2010)
67. H. Inohara, T. Segawa, A. Miyauchi, T. Yoshii, S. Nakahara, A. Raz, M. Maeda, E. Miyoshi, N. Kinoshita, H. Yoshida, M. Furukawa, Y. Takenaka, Y. Takamura, Y. Ito, N. Taniguchi, Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem. Biophys. Res. Commun. 376(3), 605-610 (2008)
68. G. Fadda, E.D. Rossi, M. Raffaelli, A. Pontecorvi, S. Sioletic, F. Morassi, C.P. Lombardi, G.F. Zannoni, G. Rindi, Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology. Eur. J. Endocrinol. 165(3), 447-453 (2011)
69. R. Jain, S. Fischer, S. Serra, R. Chetty, The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl. Immunohistochem. Mol. Morphol. 18(1), 9-15 (2010)
70. B. Cochand-Priollet, H. Dahan, M. Laloi-Michelin, M. Polivka, M. Saada, P. Herman, P.J. Guillausseau, L. Hamzi, N. Pote, E. Sarfati, M. Wassef, H. Combe, D. Raulic-Raimond, P. Chedin, V. Medeau, D. Casanova, R. Kania, Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid 21(10), 1067-1073 (2011)
71. L. Yip, C. Farris, A.S. Kabaker, S.P. Hodak, M.N. Nikiforova, K.L. McCoy, M.T. Stang, K.J. Smith, Y.E. Nikiforov, S.E. Carty, Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J. Clin. Endocrinol. Metab. 97(6), 1905-1912 (2012)
72. H. Li, K.A. Robinson, B. Anton, I.J. Saldanha, P.W. Ladenson, Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J. Clin. Endocrinol. Metab. 96(11), E1719-E1726 (2011)
73. M. Najafzadeh, C.A. Marra, L.D. Lynd, S.M. Wiseman, Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer. Value Health 15(8), 1005-1013 (2012)
74. M.N. Nikiforova, P.W. Biddinger, C.M. Caudill, T.G. Kroll, Y.E. Nikiforov, PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am. J. Surg. Pathol. 26(8), 1016-1023 (2002)
75. P. Castro, A.P. Rebocho, R.J. Soares, J. Magalhaes, L. Roque, V. Trovisco, I. Vieira de Castro, M. Cardoso-de-Oliveira, E. Fonseca, P. Soares, M. Sobrinho-Simoes, PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 91(1), 213-220 (2006)
76. L. Santarpia, J.N. Myers, S.I. Sherman, F. Trimarchi, G.L. Clayman, A.K. El-Naggar, Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116(12), 2974-2983 (2010)